Inhibitory Antibodies

Abagovomab (Anti-Human CA-125 Recombinant Antibody) is a mouse monoclonal antibody that targets the tumor-associated antigen CA-125. Abagovomab is produced by hybridoma cells in mice and can mimic human TAA, CA-125. Abagovomab can also induce humoral and cellular immune responses to ovarian cancer (oc).

Alsevalimab is a human monoclonal antibody against B7-H4.

Alvircept sudotox is a monoclonal antibody that targets the OX40 ligand (OX40L). It inhibits the interaction between OX40 and OX40L, and can be used for research on atopic dermatitis.

Anivovetmab (KIND-030) is a monoclonal antibody (IgG2 type) that targets the main capsid protein of parvovirus. Anivovetmab has potential for studying canine parvovirus infection.

Apitegromab (SRK-015) is a monoclonal antibody against myostatin. Apitegromab can be used in the research of neuromuscular diseases, including spinal muscular atrophy.

Atacicept (TACI-Ig) is a recombinant fusion protein that contains the extracellular ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and proliferation-inducing ligands. Atacicept can be used for research on B cell-mediated autoimmune diseases.

Bapotulimab (BAY-1905254) is a fully human IgG2 antibody that targets the receptor 2 with immunoglobulin-like domain (ILDR2). Bapotulimab has anti-tumor and immune-suppressive effects.

Batoclimab is a human monoclonal antibody against FcRn. It can be used in the research of autoimmune diseases mediated by pathogenic IgG antibodies.

Bexmarilimab (FP-1305) is an effective humanized anti-CLEVER-1 IgG4 antibody with an IC50 value of 4.51 nM. Bexmarilimab can induce immune switching from M2 to M1 phenotype in tumor-associated macrophages. Bexmarilimab can be used for cancer research.

Blinatumomab (Anatumomab) is a bispecific monoclonal antibody which can specifically targets the CD19 antigen present on B cells. Blinatumomab can be used for the research of acute lymphoblastic leukemia.

Briquilimab (JSP-191) is a non-toxic humanized monoclonal antibody that targets CD117 (c-Kit) and depletes hematopoietic stem cells (HSC). As the primary method for severe combined immunodeficiency (SCID), Briquilimab can clear the host bone marrow niche space, allowing for sufficient donor HSC transplantation and immune reconstitution.

Cifurtilimab (SEA-CD40) is a humanized monoclonal antibody that targets CD40. Cifurtilimab has anti-cancer activity.

Cixutumumab (IMC-A12) is a highly-affinity humanized monoclonal antibody against IGF-1R, which inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab has broad-spectrum anti-tumor activity and can be used in the research of cancers such as lung cancer, malignant tumors, leukemia, non-small cell lung cancer, and prostate cancer.

Codrituzumab is a monoclonal antibody that targets GPC3 (glypican-3). GPC3 is an oncofetal protein expressed on the surface of hepatocellular carcinoma (HCC) cells. Codrituzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor growth.

Concizumab is a monoclonal antibody (IgG4 type) that targets TFPI and can bind to the Kunitz-type protease inhibitor 2 domain of TFPI, thereby blocking its interaction with the FXa active site. Concizumab can be used in research related to hemophilia.

Edrecolomab (Panorex) is a mouse monoclonal antibody targeting the cell surface glycoprotein 17-1A, which is expressed on epithelial tissue and tumors. Edrecolomab exhibits anti-tumor activity and can be used in research for colorectal cancer.

Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody that targets a variant of MUC5AC. Ensituximab has demonstrated specificity for colorectal and pancreatic cancer.

Evinacumab (REGN1500) is a humanized monoclonal antibody (IgG4 class antibody) against ANGPTL3 (angiopoietin-like protein 3). Evinacumab can reduce plasma lipids in mice with lipid abnormalities by blocking ANGPTL3. Evinacumab can be used for research on homozygous familial hypercholesterolemia (HoFH), refractory hypercholesterolemia (including familial and non-familial), and severe hypertriglyceridemia.

Feladilimab (Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609) is a humanized IgG4 monoclonal antibody that targets the ICOS co-stimulatory molecule. Feladilimab binds to T cells expressing ICOS and has potential for cancer research.

Frunevetmab (NV-02) is a feline-derived monoclonal antibody against nerve growth factor (NGF), with a Kd of 20 pM. Frunevetmab can effectively alleviate osteoarthritis (OA) pain in cats.

Gatipotuzumab (PankoMab) is a humanized monoclonal antibody that recognizes the tumor-specific epitope of mucin-1 called TA-MUC1. Gatipotuzumab has effective tumor-specific antibody-dependent cell-mediated cytotoxicity (ADCC).

Ginisortamab (UCB6114) is a fully human IgG4P monoclonal antibody against Gremlin-1. Ginisortamab has the potential to study gastrointestinal (GI) tumors.

Glenzocimab (ACT017) is a humanized monoclonal antibody Fab fragment that targets GPVI. Glenzocimab inhibits collagen-induced platelet aggregation and has potential in the research of acute ischemic stroke.

Human IgG1 kappa, Isotype Control, a human monoclonal antibody, is an isotype control for human IgG1κ antibody.

Human IgG4 (S228P) kappa, Isotype Control, a human-derived monoclonal antibody, is an isotype control for human IgG4κ antibody.

Idactamab (INT-001) is an IgG1-κ monoclonal antibody with in vivo activity in a range of hematologic malignancies. Idactamab can be used to prepare the specific ADC MEDI7247, targeting ASCT2 (SLC1A5).

IMAB027 (ASP1650) is a specific monoclonal antibody against CLDN6, which is a tight junction membrane protein that is abnormally expressed in various types of human cancers, especially ovarian cancer. IMAB 027 has anti-tumor activity and induces apoptosis in CLDN6+ ovarian and testicular cancer cells.

Imaprelimab (PRX-003) is a humanized IgG1κ monoclonal antibody against melanoma cell adhesion molecule (MCAM). Imaprelimab is an anti-tumor agent.

Inclacumab (Anti-Human selectin P Recombinant Antibody) is a humanized IgG4 monoclonal antibody that selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits the binding of P-selectin glycoprotein ligand-1 (PSGL-1) mimetic peptide to P-selectin, with an IC50 value of 1.9 μg/mL. Inclacumab strongly inhibits cell adhesion.

Ivuxolimab is an OX40 (also known as CD134; TNFRSF4) agonistic monoclonal antibody. OX40 is a co-stimulatory receptor expressed on activated CD4+ and CD8+ T cells. Ivuxolimab has anti-tumor activity and potential immune stimulatory activity.

KWAR23 is an anti-human SIRPα antibody. KWAR23 binds to human SIRPα with high affinity and disrupts its binding to CD47. When used in combination with tumor-opsonizing antibodies, KWAR23 has anti-tumor activity and can be used for research in cancer immunotherapy.

Labetuzumab is a humanized monoclonal antibody against carcinoembryonic antigen (CEA) that can inhibit tumor growth and sensitize human medullary thyroid carcinoma xenografts to Dacarbazine chemotherapy.

Lacutamab (IPH4102) is a human monoclonal antibody (mAb) targeting the immune receptor molecule KIR3DL2, produced through recombinant technology in CHO cells. Lacutamab can be used for research on cutaneous T-cell lymphoma.

Ladiratuzumab (hLIV22) is a humanized monoclonal antibody that targets LIV-1/ZIP6. When conjugated with the microtubule inhibitor MMAE, it can form an antibody-drug conjugate (ADC) called SGN-LIV1A. Ladiratuzumab can be used for research on breast cancer.

Landogrozumab (LY2495655) is a humanized monoclonal antibody against myostatin, which effectively improves muscle volume, grip strength and function. Landogrozumab can be used in research related to muscle atrophy diseases.

Lirilumab (IPH2102) is an anti-KIR monoclonal antibody with anti-tumor activity. Lirilumab can be used for research on leukemia and squamous cell carcinoma of the head and neck (SCCHN).